The Fort Worth Press - RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

USD -
AED 3.673021
AFN 64.500085
ALL 81.04013
AMD 377.570287
ANG 1.79008
AOA 916.999994
ARS 1397.0363
AUD 1.411761
AWG 1.8025
AZN 1.703608
BAM 1.646095
BBD 2.014569
BDT 122.333554
BGN 1.67937
BHD 0.37706
BIF 2955
BMD 1
BND 1.261126
BOB 6.911847
BRL 5.198602
BSD 1.000215
BTN 90.656892
BWP 13.115002
BYN 2.867495
BYR 19600
BZD 2.011792
CAD 1.36276
CDF 2239.999889
CHF 0.769655
CLF 0.021703
CLP 856.959793
CNY 6.90065
CNH 6.899875
COP 3671.49
CRC 487.566753
CUC 1
CUP 26.5
CVE 94.875032
CZK 20.441008
DJF 177.720273
DKK 6.297485
DOP 62.625011
DZD 129.608487
EGP 46.847504
ERN 15
ETB 155.049838
EUR 0.84285
FJD 2.190198
FKP 0.732521
GBP 0.734545
GEL 2.689918
GGP 0.732521
GHS 11.005031
GIP 0.732521
GMD 73.505048
GNF 8779.999507
GTQ 7.671623
GYD 209.274433
HKD 7.816415
HNL 26.505018
HRK 6.350102
HTG 130.97728
HUF 319.496499
IDR 16823
ILS 3.063925
IMP 0.732521
INR 90.598499
IQD 1310.5
IRR 42125.000158
ISK 122.380273
JEP 0.732521
JMD 156.251973
JOD 0.709007
JPY 152.839791
KES 129.000569
KGS 87.450047
KHR 4030.0002
KMF 414.99991
KPW 899.988812
KRW 1440.150231
KWD 0.30671
KYD 0.833596
KZT 494.926752
LAK 21445.000487
LBP 85549.999541
LKR 309.456576
LRD 186.550345
LSL 15.859536
LTL 2.95274
LVL 0.60489
LYD 6.302627
MAD 9.138749
MDL 16.94968
MGA 4429.99998
MKD 51.932021
MMK 2100.304757
MNT 3579.516219
MOP 8.054945
MRU 39.900536
MUR 45.90247
MVR 15.460255
MWK 1736.501794
MXN 17.240225
MYR 3.902498
MZN 63.910195
NAD 15.960282
NGN 1352.320109
NIO 36.715003
NOK 9.53845
NPR 145.04947
NZD 1.658005
OMR 0.384491
PAB 1.000332
PEN 3.35497
PGK 4.298499
PHP 58.090162
PKR 279.600947
PLN 3.553435
PYG 6585.896503
QAR 3.64125
RON 4.291018
RSD 98.911047
RUB 77.223079
RWF 1452.5
SAR 3.750374
SBD 8.048395
SCR 13.452269
SDG 601.510014
SEK 8.92871
SGD 1.26305
SHP 0.750259
SLE 24.250324
SLL 20969.499267
SOS 571.501199
SRD 37.77903
STD 20697.981008
STN 20.95
SVC 8.752299
SYP 11059.574895
SZL 15.859726
THB 31.093501
TJS 9.417602
TMT 3.5
TND 2.83525
TOP 2.40776
TRY 43.647699
TTD 6.776109
TWD 31.448974
TZS 2599.999875
UAH 43.023284
UGX 3540.813621
UYU 38.353905
UZS 12299.999861
VES 388.253525
VND 25960
VUV 119.359605
WST 2.711523
XAF 552.10356
XAG 0.013313
XAU 0.000203
XCD 2.70255
XCG 1.802726
XDR 0.686599
XOF 549.501968
XPF 100.750245
YER 238.403969
ZAR 15.973595
ZMK 9001.200595
ZMW 18.555599
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • RIO

    -1.6100

    97.91

    -1.64%

  • CMSC

    0.0000

    23.7

    0%

  • RYCEF

    -0.0600

    16.87

    -0.36%

  • NGG

    0.5800

    91.22

    +0.64%

  • BCE

    0.1800

    25.83

    +0.7%

  • AZN

    -0.2400

    204.52

    -0.12%

  • CMSD

    -0.1280

    23.942

    -0.53%

  • BTI

    0.2800

    60.61

    +0.46%

  • GSK

    0.0500

    58.54

    +0.09%

  • RELX

    1.0800

    28.81

    +3.75%

  • BP

    -1.3600

    37.19

    -3.66%

  • VOD

    -0.0600

    15.62

    -0.38%

  • BCC

    -1.3500

    88.06

    -1.53%

  • JRI

    0.0300

    13.16

    +0.23%

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion.

Text size:

RedChip began introducing Cidara to its global microcap and small-cap investor network in 2021, when the company's market capitalization was under $100 million and its groundbreaking antiviral and antifungal programs were still largely undiscovered by the broader investment community.

"Cidara's journey from a sub-$100 million emerging growth story to a multibillion-dollar strategic acquisition by Merck is exactly the type of transformational outcome RedChip seeks to spotlight for investors," said Dave Gentry, CEO of RedChip Companies. "We were proud to share the Cidara story at a time when its innovative Cloudbreak® platform and long-acting antiviral programs were just beginning to attract institutional attention. Seeing that early science culminate in one of the largest biotech acquisitions of the year validates both Cidara's vision and the importance of bringing promising small-cap opportunities to investors early."

As detailed in Merck's announcement, the acquisition centers on CD388, Cidara's investigational long-acting, strain-agnostic antiviral designed to prevent influenza infection in individuals at high risk of complications. CD388, now in Phase 3 development, was granted Breakthrough Therapy Designation by the FDA and is viewed as a potentially first-in-class seasonal prevention solution with global commercial potential.

"Cidara exemplifies the type of emerging blue-chip story that aligns with RedChip's 33-year mission," Gentry added. "We congratulate the Cidara team on this extraordinary milestone and look forward to continuing our work discovering tomorrow's leading innovators today."

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]

--END--

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

S.Jones--TFWP